Ladan Panahi

Dr. Ladan Panahi

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in American Journal of Pharmaceutical Education
Verified
Journal Article
Closed access
CKCathy L. Koo
Cathy L. Koo
EDElaine L. Demps
Elaine L. Demps
CFCharlotte Farris
Charlotte Farris
JBJohn D. Bowman
John D. Bowman
LPLadan Panahi
Ladan Panahi
PBPaul Boyle
Paul Boyle
Objective. To determine whether a flipped classroom design would improve student performance and perceptions of the learning experience compared to traditional lecture course design in a required pharmacotherapy course for second-year pharmacy students.Design. Students viewed short online videos about the foundational concepts and answered self-assessment questions prior to face-to-face sessions involving patient case discussions.Assessment. Pretest/posttest and precourse/postcourse surveys evaluated students’ short-term knowledge retention and perceptions before and after the redesigned course. The final grades improved after the redesign. Mean scores on the posttest improved from the pretest. Postcourse survey showed 88% of students were satisfied with the redesign. Students reported that they appreciated the flexibility of video viewing and knowledge application during case discussions but some also struggled with time requirements of the course.Conclusion. The redesigned course improved student test p...

1 March 2017 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
HMHeather Miller
Heather Miller
LPLadan Panahi
Ladan Panahi
DTDaniel Tapia
Daniel Tapia
ATAndrew Tran
Andrew Tran
JBJohn D. Bowman
John D. Bowman

26 July 2022 in Cureus
Verified
Journal Article
Open access
MHMichael Horseman
Michael Horseman
LPLadan Panahi
Ladan Panahi
GUGeorge Udeani
George Udeani
ATAndrew S. Tenpas
Andrew S. Tenpas
RJRene Verduzco Jr.
Rene Verduzco Jr.
Salim SuraniSalim Surani
Salim Surani
Humans maintain core body temperature via a complicated system of physiologic mechanisms that counteract heat/cold fluctuations from metabolism, exertion, and the environment. Overextension of these mechanisms or disruption of body temperature homeostasis leads to bodily dysfunction, culminating in a syndrome analogous to exertional heat stroke (EHS). The inability of this thermoregulatory process to maintain the body temperature is caused by either thermal stress or certain drugs. EHS is a syndrome characterized by hyperthermia and the activation of systemic inflammation. Several drug-induced hyperthermic syndromes may resemble EHS and share common mechanisms. The purpose of this article is to review the current literature and compare exertional heat stroke (EHS) to three of the most widely studied drug-induced hyperthermic syndromes: malignant hyperthermia (MH), neuroleptic malignant syndrome (NMS), and serotonin syndrome (SS). Drugs and drug classes that have been implicated in these conditions include amphetamines, diuretics, cocaine, antipsychotics, metoclopramide, selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), and many more. Observations suggest that severe or fulminant cases of drug-induced hyperthermia may evolve into an inflammatory syndrome best described as heat stroke. Their underlying mechanisms, symptoms, and treatment approaches will be reviewed to assist in accurate diagnosis, which will impact the management of potentially life-threatening complications.

2 February 2022 in Medicina
Verified
Journal Article
Open access
PDF file
EAEnrique Arredondo
Enrique Arredondo
MDMonica DeLeon
Monica DeLeon
IMIshimwe Masozera
Ishimwe Masozera
LPLadan Panahi
Ladan Panahi
GUGeorge Udeani
George Udeani
TSTori L. Shiver
Tori L. Shiver
Obstructive sleep apnea (OSA) remains a prominent disease state characterized by the recurrent collapse of the upper airway while sleeping. To date, current treatment may include continuous positive airway pressure (CPAP), lifestyle changes, behavioral modification, mandibular advancement devices, and surgical treatment. However, due to the desire for a more convenient mode of management, pharmacological treatment has been thoroughly investigated as a means for a potential alternative in OSA treatment. OSA can be distinguished into various endotypic or phenotypic classes, allowing pharmacological treatment to better target the root cause or symptoms of OSA. Some medications available for use include antidepressants, CNS stimulants, nasal decongestants, carbonic anhydrase inhibitors, and potassium channel blockers. This review will cover the findings of currently available and future study medications that could potentially play a role in OSA therapy.

28 October 2021 in Medicina
Verified
Journal Article
Open access
PDF file
LPLadan Panahi
Ladan Panahi
GUGeorge Udeani
George Udeani
SHSteven Ho
Steven Ho
BKBrett Knox
Brett Knox
JMJason Maille
Jason Maille
Nearly a billion adults around the world are affected by a disease that is characterized by upper airway collapse while sleeping called obstructive sleep apnea or OSA. The progression and lasting effects of untreated OSA include an increased risk of diabetes mellitus, hypertension, stroke, and heart failure. There is often a decrease in quality-of-life scores and an increased rate of mortality in these patients. The most common and effective treatments for OSA include continuous positive airway pressure (CPAP), surgical treatment, behavior modification, changes in lifestyle, and mandibular advancement devices. There are currently no pharmacological options approved for the standard treatment of OSA. There are, however, some pharmacological treatments for daytime sleepiness caused by OSA. Identifying and treating obstructive sleep apnea early is important to reduce the risks of future complications.

26 January 2021 in Medicina
Verified
Journal Article
Open access
PDF file
LPLadan Panahi
Ladan Panahi
GUGeorge Udeani
George Udeani
MHMichael Horseman
Michael Horseman
JWJaye Weston
Jaye Weston
NSNephy Samuel
Nephy Samuel
DBDaniela Bazan
Daniela Bazan
Traditionally, the management of patients with pulmonary embolism has been accomplished with anticoagulant treatment with parenteral heparins and oral vitamin K antagonists. Although the administration of heparins and oral vitamin K antagonists still plays a role in pulmonary embolism management, the use of these therapies are limited due to other options now available. This is due to their toxicity profile, clearance limitations, and many interactions with other medications and nutrients. The emergence of direct oral anticoagulation therapies has led to more options now being available to manage pulmonary embolism in inpatient and outpatient settings conveniently. These oral therapeutic options have opened up opportunities for safe and effective pulmonary embolism management, as more evidence and research is now available about reversal agents and monitoring parameters. The evolution of the pharmacological management of pulmonary embolism has provided us with better understanding regarding the selection of anticoagulants. There is also a better understanding and employment of anticoagulants in pulmonary embolism in special populations, such as patients with liver failure, renal failure, malignancy, and COVID-19.